PT  - JOURNAL ARTICLE
AU  - Kamal, Farooq
AU  - Morrison, Cassandra
AU  - Maranzano, Josefina
AU  - Zeighami, Yashar
AU  - Dadar, Mahsa
AU - Alzheimer’s Disease Neuroimaging Initiative
TI  - Differential WMH progression trajectories in progressive and stable mild cognitive impairment
AID  - 10.1101/2022.09.21.22280209
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.09.21.22280209
4099  - http://medrxiv.org/content/early/2022/09/23/2022.09.21.22280209.short
4100  - http://medrxiv.org/content/early/2022/09/23/2022.09.21.22280209.full
AB  - Background Pathological brain changes such as white matter hyperintensities (WMHs) occur with increased age and contribute to cognitive decline. Current research is still unclear regarding the association of amyloid positivity with WMH burden and progression to dementia in people with mild cognitive impairment (MCI).Methods This study examined whether WMH burden increases differently in both amyloid-negative (Aβ-) and amyloid-positive (Aβ+) people with MCI who either remain stable or progress to dementia. We also examined regional WMHs differences in all groups: amyloid positive (Aβ+) progressor, amyloid negative (Aβ–) progressor, amyloid positive (Aβ+) stable, and amyloid negative (Aβ–) stable. MCI participants from the Alzheimer’s Disease Neuroimaging Initiative were included if they had APOE ɛ4 status and if they had amyloid measures to determine amyloid status (i.e., positive, or negative). A total of 820 MCI participants that had APOE ɛ4 status and amyloid measures were included in the study with 5054 follow-up time points over a maximum period of 13 years with an average of 5.7 follow-up timepoints per participant. Linear mixed-effects models were used to examine group differences in global and regional WMHs.Results People who were Aß– stable had lower baseline WMHs compared to both Aß+ progressors and Aß+ stable across all regions. When examining change over time, compared to Aß– stable, all groups had steeper change in WMH burden with Aß+ progressors having the largest change (largest increase in WMH burden over time).Conclusion These findings suggest that WMH progression is a contributing factor to conversion to dementia both in amyloid-positive and negative people with MCI.Competing Interest StatementThe authors have declared no competing interest.Funding StatementDr. Dadar reports receiving research funding from the Healthy Brains for Healthy Lives (HBHL), Alzheimer Society Research Program (ASRP), and Douglas Research Centre (DRC). Dr. Morrison is supported by a postdoctoral fellowship from Canadian Institutes of Health Research, Funding Reference Number: MFE-176608. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Data used in preparation of this article were obtained from the Alzheimers Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at Alzheimers Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu)